I hereby certify that this correspondence is being deposited with the United ustates Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 18547-042010US
Client Reference No.: 3295.1

Assistant Commissioner for Patents Washington, D.C. 20231

5/25/01

COPY

TOWNSEND and TOWNSEND and CREW LLP

By: Jennife K. Hardi

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

McGall and Kajisa

Application No.: 09/810,434

Filed: March 15, 2001

For: PHOSPHITE ESTER OXIDATION

IN NUCLEIC ACID ARRAY

PREPARATION

Examiner: Unassigned

Art Unit:

1645

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and

McGall and Kajisa

Application No.: 09/810,434

Page 2

no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

William B. Kezer Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor

San Francisco, California 94111-3834

Tel: 925 472-5000 Fax: 925 472-5015

WBK:jkh

SF 1216011 v1

REPORTED TO A TRACE!

Sheet

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

pstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 3

	Complete if Known	.)
Application Number	09/810,434	
Filing Date	March 15, 2001	
First Named Inventor	Glenn McGall	-
Group Art Unit	1645	
Examiner Name	Unassigned	
Attorney Docket Number	18547-042010US	

		U.S. Patent Document	U.S. PATENT DOCUM		Pages, Columns, Lines,
Examiner Initials *	Cite No.	Number Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	1	5,143,854	Pirrung et al.	9/1/92	
	2	5,242,979	Barnum et al.	9/7/93	
	3	5,252,743	Barrett et al.	10/12/93	
	4	5,288,514	Ellman	2/22/94	
	5	5,324,633	Fodor et al.	6/28/94	
	6	5,324,663	Lowe	6/28/94	
	7	5,384,261	Winkler et al.	1/24/95	
	8	5,405,783	Pirrung et al.	4/11/95	· .
	9	5,412,087	McGall et al.	5/2/95	
-	10	5,424,186	Fodor et al.	6/13/95	
	11	5,445,934	Fodor et al.	8/29/95	
	12	5,451,683	Barrett et al.	9/19/95	
,	13	5,482,867	Barrett et al.	1/9/96	
	14	5,489,678	Fodor et al.	2/6/96	
	15	5,491,074	Aldwin et al.	2/13/96	
	16	5,510,270	Fodor et al.	4/23/96	
	17	5,527,681	Holmes	6/18/96	
	18	5,545,531	Rava et al.	8/13/96	
	19	5,547,839	Dower et al.	8/20/96	
	20	5,550,215	Holmes	8/27/96	
	21	5,556,752	Lockhart et al.	9/17/96	
	22	5,571,639	Hubbell et al.	11/5/96	
.,	23	5,578,832	Trulson et al.	11/26/96	
	24	5,593,839	Hubbell et al.	1/14/97	
	25	5,599,695	Pease et al.	2/4/97	
	26	5,624,711	Sundberg et al.	4/29/97	
- :	27	5,631,734	Stem et al.	5/20/97	
	28	5,658,734	Brock, et al.	8/19/97	
	29	5,677,195	Winkler et al.	10/14/97	
	30	5,710,000	Sapolsky et al.	1/20/98	
	31	5,744,101	Fodor et al.	4/28/98	
	32	5,744,305	Fodor et al.	4/28/98	
	33	5,753,788	Fodor et al.	5/19/98	
	34	5,770,456	Holmes	6/23/98	
	35	5,800,992	Fodor et al.	9/1/98	
	36	5,831,070	Pease et al.	11/3/98	
	37	5,843,655	McGall	12/1/98	
	38	5,856,011	Sogabe	1/5/99	
	39	5,919,523	Sundberg et al.	7/6/99	
	40	6,022,963	McGall et al.	2/8/00	
	41	6,045,996	Cronin et al.	4/4/00	

Examiner	Date	•
Signature	Considered	<u>, , , , , , , , , , , , , , , , , , , </u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

titute for form 1449B/PTO

MAY 2 6 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

	Complete if Known	
Application Number	09/810,434	
Filing Date	March 15, 2001	
First Named Inventor	Glenn McGall	
Group Art Unit	1645	
Examiner Name	Unassigned	
Attorney Docket Number	18547-042010US	

					PATENT DOCUM	IEN13	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Office 3	oreign Patent Docu Number ⁴ Ki	ment nd Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T⁵
	42	PCT	WO 92/10183		Hill	6/25/92		
	43	PCT	WO 99/00730		Tremblay et al	1/7/99		
	44	PCT	WO 93/04145		Inoue et al.	3/4/93		
	45	PCT	WO 97/10365		Lockhart et al.	3/20/97		
	46	PCT	WO 92/10092		Fodor et al.	6/25/92		
	47	PCT	WO 94/10128	1	Holmes et al.	5/11/94		
	48	PCT	WO 00/61282		Glazer et al.	10/19/00		
	49	PCT	WO 00/21967		McGall et al.	04/20/00		
	50	PCT	WO 00/06771		McGall et al.	02/10/00		
	51	PCT	WO 99/54509		McGall et al.	10/28/99		
	52	PCT	WO 99/40105		Goldberg et al.	02/12/99		
	53	PCT	WO 98/39348		McGall et al.	09/11/98		
	54	PCT	WO 98/20967		Beecher et al.	05/22/98		
	55	PCT	WO 97/39151		Goldberg et al.	10/23/97		
	56	PCT	WO 97/43450		Cronin et al.	11/20/97		
	57	PCT	WO 97/27317		Lockhart et al.	07/31/97		ļ
	58	PCT	EP 742287		McGall et al.	11/13/96		<u> </u>
	59	PCT	EP 7288520		Pease et al.	08/28/96		<u> </u>
	60	EPO	EP 549107		Western et al.	12/29/97		
1	61	EPO	967217 A2		McGall et al.	12/29/99		<u> </u>

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	62	MCGALL et al., "The Efficiency of Light-Directed Synthesis of DNA Arrays on Glass Substrates" Journal of the American Chemical Society, 1997, Pages 5081-5090, Vol. 119, No. 22	
	63	LOCKHART et al.,"Expression monitoring by hybridization to high-density oligonucleotide arrays" Nature Biotechnology, 1996, Pages 1675-1680, Vol. 14	
	64	SAIZIEU et al., "Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays" Nature Biotechnology, 1998, Pages 45-48, Vol. 16	
	65	CHEE et al., "Accessing Genetic Information with High-Density DNA Arrays" Science, 1996, Pages 610-614, Vol. 274	

		 · · · · · · · · · · · · · · · · · · ·
Examiner Signature	Date Considered	 ·



PATENT APPLICATION DOCKET NO.: 2719.2017-001

March 14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Glenn McGall and Lisa Kajisa

Application No.:

09/810,434

Group Art Unit:

1635

Filed:

March 15, 2001

Examiner:

Epps, Janet L.

Confirmation No.:

6484

Title:

(Filed after payment of issue fee)

PHOSPHITE ESTER OXIDATION IN NUCLEIC ACID ARRAY

PREPARATION

VIA HAND DELIVERY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231 Sir: This Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection) under 37 CFR 1.97(b), or [X](Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination). under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) under 37 CFR 1.97(d) together with: a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee) under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

Please type a plus sign (+) inside this box

flitute for form 1449A/PTO

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known **Application Number** 09/810,434 March 15, 2001 Filing Date Glenn McGall First Named Inventor 1645 Group Art Unit Unassigned **Examiner Name** 18547-042010US Attomey Docket Number

66	McGALL et al., "High-density oligonucleotide probe arrays" Proc. SPIE-Int. Soc. Opt. Eng., 2000, Pages 106-110, Vol. 3926 (Advances in Nucleic Acid and Protein Analyses, Manipulation, and Sequencing)
67	WALLRAFF et al., "Lithographic techniques for the fabrication of oligonucleotide arrays" J. Photopolym. Sci. Technol., 2000, Pages 551-558, Vol 13
68	GLAZER et al., "High Surface Area Substrates for DNA Arrays" Mat. Res. Soc. Symp. Proc., 1999, Pages 371-6, Vol. 576
69	FIDANZA et al., "High-Density Nucleoside Analog Probe Arrays for Enhanced Hybridization" Nucleosides and Nucleotides, 1999, Pages1293-1295, Vol. 18
70	HACIA et al., "Enhanced High Density Oligonucleotide Array Based Sequence Analysis using Modified Nucleotide Triphosphates" Nucleic Acids Res., 1998, Pages 4975-4982, Vol. 26
71	PIRRUNG et al., "Proofing of Photolithographic DNA synthesis with 3', 5' – dimethoxybenzoinyloxycarbonyl-protected deoxy-nucleoside phosphoramidites" J.Org. Chem, 1998, Pages 241-246, Vol. 63

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



TO THE U.S. PATENT AND TRADEMARK OFFICE
Please stamp the date of receipt of the following document(s) and return this card to us

RE: Mc TITLE OF DOCUME Information Disclosur PTO-1449 References 71		01PE 673
Application No.: File No	09/810,434 018547-042010	THE PROPERTY OF THE PARTY OF TH
Date Due	5/25/01	
Date Mailed: Atty/Secty SF 1018344 v1	WBK/jkh	

Staten	ieni One	JEI 3/ C	SFR 1.97(E)
[]	any co	mmuni	nformation contained in this Information Disclosure Statement was first cited in cation from a foreign patent office in a counterpart foreign application not more on the filing of this Information Disclosure Statement; or
[]	knowle	unication edge of informa	formation contained in this Information Disclosure Statement was cited in a on from a foreign patent office in a counterpart foreign application, and, to the the undersigned, after making reasonable inquiry, no item of information contained tion disclosure statement was known to any individual designated in 37 CFR han three months prior to the filing of this Information Disclosure Statement.
Staten	ent Und	der 37 ((Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
[]	commi	unication t receiv	information contained in the Information Disclosure Statement was cited in a sign from a foreign patent office in a counterpart application and this communication red by any individual designated in § 1.56(c) more than thirty days prior to the aformation Disclosure Statement.
[X]	Enclos	ed here	with is form PTO-1449:
	[X]	Сору	of the cited reference is enclosed.
	[]	Applic	s of cited references are enclosed except those entered in prior application, U.S. eation No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]
	[]	The lis	sted references were cited in the enclosed International Search Report in a rpart foreign application.
	[]	The "c	oncise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:
•		[]	the explanation provided on the attached sheet. •
		[]	the explanation provided in the Specification.
		[]	submission of the enclosed International Search Report.
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
		[]	the enclosed English language abstract.

niner's ials	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
AFAIR. BERLINES ALBERTAN	Examiner	Date		

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

], to which priority under

It is requested that the information disclosed herein be made of record in this application.

those entered in prior application, U.S. Application No. [

35 U.S.C. 120 is claimed.

REMARKS

Applicants are submitting this Supplemental IDS with unpublished data obtained by the inventors of the subject application. The excerpt included herewith as "Reference AR" shows the results of a single experiment with statistically inconclusive results. Applicants draw the Examiner's attention to the Table in Reference AR. The results depicted in the table show that hybridizing a sequence to a probe that was prepared with an oxidant solution containing 10% water and 0.01 M iodine produced an average relative hybridization signal intensity of 200. Similar hybridizations where the oxidant solution contained 10% water and 0.10 M iodine (the standard concentration) produced average relative hybridization signal intensities of 166 and 278, for an overall mean of 222 and a standard deviation of 56. Although the average relative signal intensity of the trial using 0.01 M iodine is less than the mean of the trials using 0.10 M iodine, the average relative intensity of the trial using 0.01 M iodine is well within one standard deviation of the other trials.

M	[etho	d of payment:				
[]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.				
[]	Please charge Deposit Account 08-0380 in the amount of \$[enclosed.]. A copy of this Statement is			

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Jesse A. Fecker

Registration No.: 52,883 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133 Dated: 3-14-03

disconcept. Total interest of								
H	49 REPRODUCED			ATTORNEY DOCKET NO. 2719.2017-001 APPLICATION NO. 09/810,434				
OIP	INFO	RMATION DISCLOSURE CI	ITATION	APPLICANT Glenn McGall and Lisa Kajisa				
MAY 2	6 2004	MARCH 13, 2003		FILING DATE March 15, 2001	CONFIRMA 6484	TION NO.	GROUP	
		Ž			10101			
& TBAL	ENARY	T	U.S.	PATENT DOCUMENTS	T			
EXAM- INER INI- TIAL		DOCUMENT NU	MBER	ISSUE DATE / PUBLICATION DATE		NAME		
	AA							
	AB							
	AC							
	AD							
	AE	The state of the s						
	AF							
	AG							
	AH AI - AJ							
	AK							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL YES	ATION ON
	AL_							
	AM							
	AN							
	AO	-	•					
	AP			′				
	AQ							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	AR	"Oxidizing Agent Study" (unpublished data)						
	AS							
	AT							
EXAMIN	NER		· · · · · · · · · · · · · · · · · · ·	DATE CONSIDERED				

Oxidizing Agent Study

A nucleic acid array was prepared on a silicon substrate, as described in the Declaration of Glenn McGall Under 37 C.F.R. § 1.132 (hereinafter "the Declaration"). The iodine concentration in the solution used to oxidize phosphite esters to phosphate esters was varied from 0.01 M to 0.10 M.

After preparation, the silicon substrate was processed into chips according to the procedure described in the Declaration. The chips were hybridized with the Human Full-Length assay, which is a standard product available from Affymetrix, for 30 minutes at 35°C. As described in the Declaration, the average relative hybridization signal intensity is a measure of the functional performance of the nucleic acid array. An increased average relative hybridization signal intensity indicates enhanced functional performance of the nucleic acid array.

The results are as follows:

TABLE


Iodine Concentration	Average Relative Hybridization Signal Intensity		
0.01 M	200		
0.02 M	338		
0.05 M	299		
0.10 M	166		
0.10 M	278		

The mean of the two experiments using 0.10 M iodine in the oxidant solution is 222, with a standard deviation of 56.

COPY FAX

To: Jesse A. Fecker, Esq.

From: J.F. Brown & Assoc.



Initials:	LMT/JA	.F/dgl	Docket No.:	2719.2017-001	Date: 03	
w 611	DOI TME	NTAL INF	ORMATION	ing documents via DISCLOSURES	HAND DELI RECEIVED FAMEMENSO	VERY: 0/2960
X Fo X Co	rm PTO-l py of doc leck for \$ ppy of Inte	1449 (1 page ument AR :	e) Is noted in 144	9 03 MA Authorization	R 17 PM 12 on to Charge	ni kees
_ 0	her					
Applica Applica Title:	ints: ition No.:	Glenn McC 09/810,434 PHOSPHI	Gall <i>et al</i> . TE ESTER O	Filed: March 1 XIDATION IN NI	5, 2001 JCLEIC ACU	D ARRAY
Thata w	eceived by top\::ODMA/I	the PTO:	Age;381602;1	,		